Skip to main content
SpringerLink
Log in

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Gemcitabine is a new deoxycytidine analog that exhibits significant cytotoxicity against a variety of cultured murine and human tumor cells. The cytotoxic action of gemcitabine appears to be due to the inhibition of DNA synthesis by inhibition of ribonucleotide reductase and by competition with dCTP for incorporation into DNA. We have previously shown that gemcitabine, but not cytosine arabinoside (ara-C), has a broad spectrum of antitumor activity against 7 different types of murine solid tumors. The activity of gemcitabine was schedule dependent. To further characterize its activity, gemcitabine was tested against 12 human carcinoma xenografts. When given on an every 3 day × 4 schedule, the following percent inhibitions (at maximally tolerated doses [MTD]; MTD/2) in tumor growth were seen: MX-1 mammary (93%; 80%), CX-1 colon (92%; 82%), HC-1 colon (96%; 92%), GC3 colon (98%; 94%), VRC5 colon (99%; 100%), LX-1 lung (76%; 61%), CALU-6 lung (75%; 38%), NCI-H460 lung (45%; 46%), HS766T pancreatic (73%; not tested), PaCa-2 pancreatic (69%; 40%), PANC-1 pancreatic (70%; 60%), and BxPC-3 pancreatic (9%; 19%). In contrast, only the LX-1 lung carcinoma xenograft was responsive to ara-C treatment, which inhibited tumor growth by a marginal 62 percent. Thus, like its activity against murine solid tumors, gemcitabine has excellent antitumor activity against a broad spectrum of human solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hertel LW, Kroin JS, Misnr JW, Tustin JM: Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406–2409, 1988

    Article  CAS  Google Scholar 

  2. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ: Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248:2481–2486, 1982

    Article  PubMed  CAS  Google Scholar 

  3. Chabner BA, Meyers CE: Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. J.B. Lippincott, Philadelphia, pp 167, 1982

    Google Scholar 

  4. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 50:4417–4422, 1990

    PubMed  CAS  Google Scholar 

  5. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211–214, 1991

    PubMed  CAS  Google Scholar 

  6. Boven E, Schipper H, Erkelens CAM: The influence of the schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer 68:52–56, 1993

    PubMed  CAS  Google Scholar 

  7. Peters GJ, Schornagel JH, Milano GA: Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17:123–156, 1993

    PubMed  CAS  Google Scholar 

  8. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45–55, 1993

    Article  PubMed  CAS  Google Scholar 

  9. Houghton JA, Taylor DM: Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 37:213–223, 1978

    PubMed  CAS  Google Scholar 

  10. Schultz RM, Merriman RL, Tom JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5:223–228, 1993

    PubMed  CAS  Google Scholar 

  11. Worzalla JF, Bewley JR, Grindey GB: Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 8:241–251, 1990

    Article  PubMed  CAS  Google Scholar 

  12. Bovin E, Winograd B: The Nude Mouse in Oncology Research. CRC Press, Boca Ratan, Fl, p 135, 1991

    Google Scholar 

  13. Wils JA: Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 9:1027–1032, 1989

    PubMed  CAS  Google Scholar 

  14. Chang BK: Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture. Cancer Treat Rep 57:355–361, 1983

    Google Scholar 

  15. Chang BK, Fredericks W, Rustum YM, Baker RM: Levels of P-glycoprotein in pancreatic cancer cells lines: relation to inherent drug resistance. Proc Am Soc Clin Oncol 7: 115(abstr), 1988

    Google Scholar 

  16. Huang P, Chubb S, Hertel LW et al.: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6100–6117, 1991

    Google Scholar 

  17. Heinemann V, Xu Y-Z, Chubb S et al.: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567–572, 1990

    PubMed  CAS  Google Scholar 

  18. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031, 1988

    PubMed  CAS  Google Scholar 

  19. Plunkett W, Grindey GB: Pharmacokinetics of the 5′-triphosphates of arabinosylcytosine and 2′,2′-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser 18:77–79, 1987

    PubMed  CAS  Google Scholar 

  20. Fujita M, Fujita F, Inaba H, Taguchi T: Antitumor activity of LY188011, a new deoxydytidine analog, against human cancers xenografted into nude mice. Jpn J Cancer Chemother 21:517–523, 1994

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly & Co, 46285, Indianapolis, IN

    R. L. Merriman, L. W. Hertel, R. M. Schultz, P. J. Houghton, J. A. Houghton, P. G. Rutherford, L. R. Tanzer, G. B. Boder & G. B. Grindey

  2. St. Jude Children's Hospital, 38101, Memphis, TN, USA

    P. J. Houghton & J. A. Houghton

Authors
  1. R. L. Merriman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. W. Hertel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. M. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. J. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. A. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. G. Rutherford
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. R. Tanzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. B. Boder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. B. Grindey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merriman, R.L., Hertel, L.W., Schultz, R.M. et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14, 243–247 (1996). https://doi.org/10.1007/BF00194526

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194526

Key words

Search

Navigation